S

Synthaverse SA
WSE:SVE

Watchlist Manager
Synthaverse SA
WSE:SVE
Watchlist
Price: 4.14 PLN -2.47% Market Closed
Market Cap: 293m PLN
Have any thoughts about
Synthaverse SA?
Write Note

Net Margin
Synthaverse SA

4.3%
Current
10%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
4.3%
=
Net Income
2.5m
/
Revenue
57.4m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
PL
Synthaverse SA
WSE:SVE
292m PLN
4%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
317.9B USD
9%
US
Amgen Inc
NASDAQ:AMGN
141.7B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.9B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
135.7B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.4B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-14%
Country PL
Market Cap 292m PLN
Net Margin
4%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 317.9B USD
Net Margin
9%
Country US
Market Cap 141.7B USD
Net Margin
13%
Country US
Market Cap 117.1B USD
Net Margin
0%
Country US
Market Cap 104.9B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 135.7B AUD
Net Margin
18%
Country US
Market Cap 78.4B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36B EUR
Net Margin
-14%
No Stocks Found

Synthaverse SA
Glance View

Market Cap
292m PLN
Industry
Biotechnology

Biomed Lublin Wytwornia Surowic i Szczepionek SA engages in the manufacture of pharmaceutical products. The company is headquartered in Lublin, Woj. Lubelskie and currently employs 234 full-time employees. The company went IPO on 2011-07-29. The firm focuses on the production of drugs in the field of immunotherapy. Synthaverse SA offers its services in the field such as: oncological immunotherapy, Immunotherapy in Serological Conflict, Passive immunotherapy in hepatitis B, Active anti-tuberculosis immunotherapy, Gynecology and Proctology, Probiotics, Laboratory reagents. The firm offers injection drugs, lyophilisates of active substances in sterile sealed vials, active substances and drugs based on surface and submerged biological culture, suppository forms of drugs. The firm supplies its products to 50 countries around the world.

SVE Intrinsic Value
6.95 PLN
Undervaluation 40%
Intrinsic Value
Price
S

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
4.3%
=
Net Income
2.5m
/
Revenue
57.4m
What is the Net Margin of Synthaverse SA?

Based on Synthaverse SA's most recent financial statements, the company has Net Margin of 4.3%.